ClinicalTrials.gg

Program

Docetaxel

Also written as “docetaxel”, “Taxotere” and “HB1801”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms · Stomach Neoplasms · Lung Neoplasms, led by 27 companies.

Furthest: phase 4, since Jan 18, 2006142 company-led studies, 15 open or runningNext primary completion: Dec 16, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi540 open or runningphase 4since Jan 18, 2006Nov 1, 1999none ahead
Hoffmann-La Roche220 open or runningphase 4since Aug 5, 2005Feb 12, 2004none ahead
CSPC Pharmaceutical Group1511 open or runningphase 3since Apr 20, 2023Mar 10, 2021Dec 16, 2026phase 3 · NCT06747338
Eli Lilly81 open or runningphase 3since Nov 1, 2004Nov 1, 2004May 2027phase 2 · NCT05999994
Pfizer70 open or runningphase 2since Jan 4, 2002Jan 4, 2002none ahead
GlaxoSmithKline60 open or runningphase 2since Jul 17, 2003Jul 17, 2003none ahead
Amgen40 open or runningphase 2since Jul 5, 2000Jul 5, 2000none ahead
Merck30 open or runningphase 2since Oct 4, 2007Oct 4, 2007none ahead
novacea30 open or runningphase 3since Aug 9, 2002Aug 9, 2002none ahead
Novartis20 open or runningphase 3since Jun 29, 2004Jun 29, 2004none ahead
Samyang Biopharmaceuticals20 open or runningphase 1since Mar 21, 2011Mar 21, 2011none ahead
academy-military-medical-science-china10 open or runningphase 2since Jul 14, 2008Jul 14, 2008none ahead
Chong Kun Dang Pharmaceutical10 open or runningphase 1since Nov 23, 2009Nov 23, 2009none ahead
healthcare-global-enterprise-ltd10 open or runningphase 2since Sep 29, 2016Sep 29, 2016none ahead
hope-cancer-institute-inc10 open or runningphase 2since Nov 1, 1999Nov 1, 1999none ahead
Ionis Pharmaceuticals10 open or runningphase 2since Nov 2, 2010Nov 2, 2010none ahead
lidds-ab10 open or runningphase 1since Mar 18, 2021Mar 18, 2021none ahead
nanology-llc10 open or runningphase 1since Feb 5, 2020Feb 5, 2020none ahead
oshadi-drug-administration10 open or runningphase 2since May 7, 2014May 7, 2014none ahead
relmada-therapeutics-inc11 open or runningphase 2since Aug 8, 2024Aug 8, 2024Nov 2027phase 2 · NCT06663137
Sarah Cannon Research Institute10 open or runningphase 2since Jun 27, 2007Jun 27, 2007none ahead
shanghai-miracogen-inc11 open or runningphase 3since Feb 22, 2023Feb 22, 2023none ahead
Simcere Pharmaceutical Group10 open or runningphase 1since May 25, 2020May 25, 2020none ahead
Sumitomo Pharma10 open or runningphase 1since Dec 7, 2020Dec 7, 2020none ahead
Swedish Orphan Biovitrum10 open or runningphase 3since Feb 5, 2003Feb 5, 2003none ahead
zhuhai-beihai-biotech-co-ltd11 open or runningphase 2since Dec 9, 2024Dec 9, 2024none ahead
zivena10 open or runningphase 2since May 11, 2004May 11, 2004none ahead

Also a collaborator on its studies: parexel, jazz-pharmaceuticals-ireland-limited, baili-bio-chengdu-pharmaceutical-co-ltd, clovis-oncology-inc, Astellas Pharma, Exelixis, Gilead Sciences, iteos-belgium-sa, intas-pharmaceuticals-ltd, lambda-therapeutic-research-ltd, medigen-biotechnology-corporation, us-biotest-inc, quintiles-inc, mds-pharma-services, AstraZeneca and Regeneron Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Oct 13, 2008.

  1. Feb 22, 2023shanghai-miracogen-inc's first study: phase 3 study in Advanced or Metastatic Urothelium CancerNew to shanghai-miracogen-incshanghai-miracogen-inc · NCT05754853 · 290 planned · China
  2. Apr 20, 2023Phase 3 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT05838066 · 880 planned · China
  3. May 8, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT05863325 · 80 planned · China
  4. Aug 14, 2023Phase 2 study in NeoplasmsEli Lilly · NCT05999994 · 105 planned · United States, Australia, Belgium and more
  5. Feb 28, 2024Phase 3 study in Stomach NeoplasmsCSPC Pharmaceutical Group · NCT06296706 · 630 planned · China
  6. Mar 13, 2024Phase 3 study in Squamous Cell Non-small Cell Lung CancerCSPC Pharmaceutical Group · NCT06319313 · 534 planned
  7. Jun 24, 2024Phase 3 study in Advanced Pancreatic CancerCSPC Pharmaceutical Group · NCT06492941 · 142 planned
  8. Aug 8, 2024relmada-therapeutics-inc's first study: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNew to relmada-therapeutics-increlmada-therapeutics-inc · NCT06663137 · 70 planned · Israel
  9. Dec 9, 2024zhuhai-beihai-biotech-co-ltd's first study: phase 2 study in Urinary Bladder NeoplasmsNew to zhuhai-beihai-biotech-co-ltdzhuhai-beihai-biotech-co-ltd · NCT06732531 · 48 planned · China
  10. Dec 13, 2024Phase 3 study in Early or Locally Advanced HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT06747338 · 520 enrolled · China
  11. Jul 15, 2025Phase 2 study in Advanced Breast CancerCSPC Pharmaceutical Group · NCT07083505 · 60 planned
  12. Aug 7, 2025Phase 2 study in HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT07116824 · 80 planned
  13. Feb 12, 2026Phase 3 study in Resectable HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT07441460 · 1,800 planned · China
  14. Aug 28, 2026Phase 3 study in HER2-Negative Advanced Breast CancerCSPC Pharmaceutical Group · NCT07805135 · 430 planned

Ahead

  1. Dec 16, 2026Primary completion: phase 3 study in Early or Locally Advanced HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT06747338
  2. May 2027Primary completion: phase 2 study in NeoplasmsEli Lilly · NCT05999994
  3. Nov 2027Primary completion: phase 2 study in Non-Muscle Invasive Bladder Neoplasmsrelmada-therapeutics-inc · NCT06663137
  4. Jun 1, 2028Primary completion: phase 3 study in HER2-Negative Advanced Breast CancerCSPC Pharmaceutical Group · NCT07805135

TargetBeta

“Tubulin inhibitor; Tubulin stabiliser”ChEMBL 37, by rule

Other programs on the same 15 targets

ProgramCompanyFurthest phaseStudies
PaclitaxelruleHoffmann-La Rochephase 4202
cabazitaxelruleSanofiphase 421
VinblastineruleTakedaphase 44
desoxyepothilone Brulebeijing-biostar-pharmaceuticals-co-ltdphase 319
plinabulinrulebeyondspring-pharmaceuticals-incphase 38

Studies

The newest 60 of 142 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07805135HER2-Negative Advanced Breast Cancer3Not yet recruitingCSPC Pharmaceutical GroupJun 1, 2028430
NCT07441460Resectable HER2-positive Breast Cancer · China3RecruitingCSPC Pharmaceutical GroupAug 7, 20341,800
NCT07116824HER2-positive Breast Cancer2Not yet recruitingCSPC Pharmaceutical GroupJul 15, 202680
NCT07083505Advanced Breast Cancer2Not yet recruitingCSPC Pharmaceutical GroupOct 11, 202660
NCT06747338Early or Locally Advanced HER2-positive Breast Cancer · China3Active, not recruitingCSPC Pharmaceutical GroupDec 16, 2026520
NCT06732531Urinary Bladder Neoplasms · China2Recruitingzhuhai-beihai-biotech-co-ltdDec 202548
NCT06663137Non-Muscle Invasive Bladder Neoplasms · Israel2Recruitingrelmada-therapeutics-incNov 202770
NCT06492941Advanced Pancreatic Cancer3Not yet recruitingCSPC Pharmaceutical GroupApr 14, 2026142
NCT06319313Squamous Cell Non-small Cell Lung Cancer3Not yet recruitingCSPC Pharmaceutical GroupJul 1, 2026534
NCT06296706Stomach Neoplasms · China3RecruitingCSPC Pharmaceutical GroupJun 1, 2026630
NCT05999994Neoplasms · United States, Australia, Belgium and more2RecruitingEli LillyMay 2027105
NCT05863325Carcinoma, Non-Small-Cell Lung · China2RecruitingCSPC Pharmaceutical GroupMar 202480
NCT05838066Breast Neoplasms · China3RecruitingCSPC Pharmaceutical GroupJul 31, 2025880
NCT05754853Advanced or Metastatic Urothelium Cancer · China3Recruitingshanghai-miracogen-incOct 2025290
NCT05705635Gastric Adenocarcinoma · China2UNKNOWNCSPC Pharmaceutical GroupMay 2023100
NCT05616494Pancreatic Neoplasms · China2RecruitingCSPC Pharmaceutical GroupDec 31, 202453
NCT05325229Platinum-resistant Recurrent Ovarian Cancer · China2UNKNOWNCSPC Pharmaceutical GroupDec 202494
NCT05027204Squamous Cell Carcinoma of Head and Neck · China2UNKNOWNCSPC Pharmaceutical GroupOct 31, 202394
NCT04810208Solid Tumor · Denmark, Lithuania, Sweden1Terminatedlidds-abOct 7, 20216
NCT04811118Advanced Solid Tumors · China1UNKNOWNCSPC Pharmaceutical GroupOct 31, 202227
NCT04725188Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more2CompletedMerckJan 26, 2023255
NCT04666129Metastatic Castration-Resistant Prostate Cancer · United States1CompletedSumitomo PharmaMay 28, 202448
NCT04471428Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more3CompletedHoffmann-La RocheSep 28, 2022366
NCT04413227NSCLC · China1UNKNOWNSimcere Pharmaceutical GroupMay 31, 202130
NCT04404140Prostatic Neoplasms, Castration-Resistant · France, Italy, Spain and more1TerminatedHoffmann-La RocheOct 14, 20226
NCT04260360Carcinoma, Renal Cell1Withdrawnnanology-llcJun 20220
NCT03739710Neoplasms · United States, Canada, France and more2CompletedGlaxoSmithKlineMay 2, 2024175
NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more2TerminatedHoffmann-La RocheOct 14, 2025314
NCT02985255Tongue Neoplasms · India2UNKNOWNhealthcare-global-enterprise-ltdJun 201730
NCT02831491Carcinoma, Non-Small-Cell Lung2WithdrawnEli LillyJul 20170
NCT02748213Breast Neoplasms · Australia, Brazil, Canada and more2CompletedHoffmann-La RocheMar 2006225
NCT02605915Breast Neoplasms · United States1CompletedHoffmann-La RocheNov 13, 201998
NCT02445586Breast Neoplasms · India4CompletedHoffmann-La RocheSep 26, 201852
NCT02419742Breast Neoplasms · India4CompletedHoffmann-La RocheJun 24, 2021110
NCT02402712Breast Neoplasms · Belgium, Bulgaria, Canada and more3CompletedHoffmann-La RocheFeb 22, 2019418
NCT02274610Solid Tumor1CompletedSamyang BiopharmaceuticalsNov 201518
NCT02134990Carcinoma, Non-Small-Cell Lung · Israel2UNKNOWNoshadi-drug-administrationJan 201920
NCT02005549Breast Neoplasms · Austria2CompletedHoffmann-La RocheApr 200818
NCT01938456Carcinoma, Non-Small-Cell Lung1WithdrawnGlaxoSmithKlineJul 20140
NCT01862081Breast Neoplasms · United States, Belgium, Canada and more1CompletedHoffmann-La RocheJun 9, 201780
NCT01718353Prostate Cancer Metastatic · United States, Canada2CompletedSanofiAug 201563
NCT01515748Stomach Neoplasms · Korea, Republic of3CompletedSanofiJan 21, 2019530
NCT01336582Solid Tumor · Korea, Republic of1CompletedSamyang BiopharmaceuticalsApr 201242
NCT01266512Lung Neoplasms · Hong Kong2CompletedSanofiMar 201434
NCT01234025Castrate-Resistant Prostate Cancer · United States, Hungary, Poland and more2CompletedIonis PharmaceuticalsMay 2013113
NCT01220128Breast Neoplasms · United States, Belgium, France and more2TerminatedGlaxoSmithKlineNov 14, 201466
NCT01148615Neoplasms · China1CompletedSanofiSep 201120
NCT01038661Lung Neoplasms · China3CompletedSanofiAug 2012375
NCT01019941Advanced Solid Cancers · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalAug 201044
NCT00964704Breast Neoplasms2WithdrawnHoffmann-La RocheAug 20130
NCT00934856Breast Neoplasms · United States, France, Spain and more2CompletedHoffmann-La RocheOct 201398
NCT00927589Solid Cancers · United States1CompletedHoffmann-La RocheFeb 201359
NCT00916097Head and Neck Neoplasms · Algeria, Morocco, Tunisia2CompletedSanofiNov 200566
NCT00845910Breast Neoplasms · Taiwan2TerminatedHoffmann-La RocheMay 201122
NCT00819728Carcinoma, Non-Small-Cell Lung · United States2CompletedSanofi35
NCT00816543Stomach Neoplasms · Korea, Republic of2CompletedSanofiMay 201241
NCT00811447Stomach Neoplasms · China3CompletedSanofiJun 2012243
NCT00774241Breast Neoplasms4WithdrawnHoffmann-La RocheNov 20130
NCT00773695Breast Neoplasms · Norway2CompletedHoffmann-La RocheNov 9, 2022150
NCT00826852Lung Neoplasms · Turkey2CompletedSanofiJul 200949

How it is read

Names in the registry

  • “Docetaxel”, 93 entries
  • “docetaxel”, 37 entries
  • “Taxotere”, 9 entries
  • “HB1801”, 8 entries
  • “Docetaxel for injection (Albumin-bound)”, 4 entries

Codes read as this program: CKD810.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.